Current treatments for recurrent bacterial vaginosis leave many patients dissatisfied
A new study presented at ISSWSH highlights patient dissatisfaction with current treatments for recurrent bacterial vaginosis, emphasizing the need for more effective therapies and improved provider communication.
Image Credit: © rocketclips - stock.adobe.com.
A new study presented at the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting highlights significant dissatisfaction among patients with recurrent bacterial vaginosis (BV), underscoring the need for more effective treatments and improved communication between patients and healthcare providers.
Bacterial vaginosis is characterized by an imbalance in the vaginal microbiota, leading to symptoms such as discharge and odor.
Recurrent BV—defined as 3 or more episodes within a year—remains a persistent challenge, with recurrence rates reaching up to 50% within 6 to 12 months of treatment.2
The condition is associated with increased risks of preterm birth, pelvic inflammatory disease, sexually transmitted infections, and negative mental health effects.
Researchers surveyed individuals who had experienced recurrent BV, collecting data through online support groups and social media. Participants answered questions about their symptoms, treatment experiences, and interactions with healthcare providers.
Findings revealed that 77% of respondents continued to experience moderate to severe symptoms despite adherence to prescribed treatments. Many had tried multiple therapies, including metronidazole, boric acid, and probiotics, yet none provided consistent relief.
Metronidazole, the most effective treatment in the study, was successful for only 25.6% of participants. In addition, lifestyle modifications frequently recommended by clinicians showed little reliable benefit.
Patient dissatisfaction with both treatment outcomes and provider communication was evident. Only 20% of respondents reported any level of satisfaction with their treatment, while 60% indicated that recurrent BV had a moderate or greater impact on their well-being.
Additionally, 79% of participants felt their concerns were addressed by their provider only half of the time or less.
The study emphasizes the need for healthcare providers to improve patient engagement and communication, ensuring that individuals with recurrent BV receive both effective care and adequate support.
Researchers suggest that expanding provider education on sexual and reproductive health could enhance understanding and empathy, ultimately leading to better treatment strategies and health outcomes.
References:
1. Spagnolo S, Tiffany K, Zapata I, Reynolds A. Recurrent Bacterial Vaginosis: Patient Insights on Management and Clinician Support. Poster. Presented at: International Society for the Study of Women's Sexual Health Annual Meeting. https://www1.statusplus.net/misc/posters/isswsh/atlanta2025/search/poster/38?redirect=pm
2. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478-1486. doi:10.1086/503780
Becoming involved in health coverage and payer reimbursement issues
August 20th 2021In this podcast episode, host Scott Kober is joined by experts Robert McDonald, MD, MBA, and Karla Loken, DO, OBGYN, FACOOG, to discuss ways that practicing ob-gyns can get involved in health coverage and reimbursement issues.
Listen
